Business Development (14)

Challenge A venture-backed biotech company developing a clinical stage asset for the treatment of early-stage cancer was populating a data room and preparing for negotiations with a major pharma...

Challenge An established generics company looking to acquire the French rights of an existing product franchise needed to perform regulatory and clinical due diligence on the French dossier.

Challenge A major European venture capital investor needed to analyze the business plan of a novel point-of-care diagnostics company.

Challenge After a seed investment, Evgen, a start-up biotech had built an IP portfolio in the field of glucosinolates, chemicals found in brassica vegetables, that are potent inducers of...

Challenge Our client, a commercial stage biotech company focused on rare and ultra-rare diseases was seeking to build its pipeline of development products. Whilst it had an established business...

Challenge A listed North American firm needed support with the identification of early-stage in-licensing or acquisition opportunities in the highly competitive field of regenerative medicine....

Challenge A listed North American company needed hands-on support with the identification, assessment and in-licensing of early-stage oncology assets.

Challenge A well-capitalized European pharma company needed on-the-ground support with a search for late stage therapeutics, devices and diagnostics acquisition opportunities in the US. Alacrita was...

Challenge A listed North American company needed support with the identification, assessment and in-licensing of early-stage oncology assets.

Challenge We have conducted multiple due diligence projects, below are three examples:

Challenge: Alacrita conducted an assessment of an AAV gene therapy for an ophthalmic indication, focusing on market potential, technical and regulatory issues and identification of key risks.

Alzheimer's due diligence Our client, a major pension fund, was considering an investment opportunity in a Phase III neuroscience company. The company was developing a small molecule to provide...